Bispecifics & ADC Scientist for AI-Driven Preclinical R&D

Mercor; New York (NY); Remote; USD 150,000 - 230,000; Full time

Job summary

Mercor is partnering with a venture-backed AI lab building frontier AI platforms and physics-based foundation models for chemistry, materials science, and drug discovery. They're extending their platform into new areas of pharmaceutical development and are looking for hands-on ADC and/or bispecific experts to help guide what they build.

If you are a preclinical R&D scientist who has taken drug programs from the bench toward the clinic— and curious how AI reshapes drug discovery— this is a

Qualifications

• Hands-on preclinical R&D experience at a company developing its own drug assets.
• Direct experience with ADCs and/or bispecific antibodies.
• Experience across discovery biology, medicinal chemistry, protein/antibody engineering, computational, PK-PD, or toxicology.
• 5+ years of relevant industry R&D experience.

Responsibilities

• Review technical materials and real-world R&D data across ADC and/or bispecific programs.
• Label, classify, and annotate scientific data and model outputs to improve model performance.
• Provide expert perspective on key scientific and development decisions (target/modality selection, optimization, risk).
• Help define structure and quality standards for the client's dataset pipeline.
• Participate in expert discussions, interviews, and research engagements.

Skills

Preclinical R&D

ADCs

Bispecific antibodies

Antibody engineering

Pharmacology/PK-PD

Translational biology

In vivo

CMC/formulation

Job description

Mercor is partnering with a venture-backed AI lab building frontier AI platforms and physics-based foundation models for chemistry, materials science, and drug discovery. They're extending their platform into new areas of pharmaceutical development and are looking for hands-on ADC and/or bispecific experts to help guide what they build.

If you are a preclinical R&D scientist who has taken drug programs from the bench toward the clinic— and curious how AI reshapes drug discovery— this is a